- Baxter International (NYSE:BAX) Q2 Results ($M): Total Revenues: 2,585 (+4.4%); Hospital Products: 1,620 (+6.2%); Renal: 965 (+1.7%).
- Fluid Systems: 586 (+13.1%); Integrated Pharmacy Solutions: 563 (+2.7%).
- Net Income: 1,212 (+265.1%); Non-GAAP Net Income: 256 (+139.3%); EPS: 2.19 (+265.0%); Non-GAAP EPS: 0.46 (+142.1%).
- 2016 Guidance: Sales Growth: 1 - 2%; EPS: $8.87 - 8.94 from $8.94 - 9.06.
- Q3 Guidance: Sales Growth: 2 - 3%; EPS: $0.25 - 0.29.
Baxter Q2 top line up 4%; net income and EPS up 265%; EPS guidance lowered
Recommended For You
More Trending News
About BAX Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
BAX | - | - |
Baxter International Inc. |